Emily Day, Ph.D.
590 Avenue 1743
Newark, DE 19713
- Ph.D. in Bioengineering, 2011, Rice University
- B.S. in Physics, Minor in Mathematics, 2006, University of Oklahoma
- Postdoctoral Fellow, 2011-2013, Department of Chemistry, Northwestern University
- Nanomedicine for cancer and maternal-fetal health
- Gene regulation
- Photothermal therapy
- Drug delivery
AREAS OF SPECIAL INTEREST
The Day Lab develops innovative nanomaterials that enable high precision therapy of cancer and other diseases, and elucidates how nanoparticle architecture impacts function by studying nano/bio interactions from the subcellular to whole organism level. The nanoparticles we develop enable high precision by: (1) inhibiting molecules that are expressed exclusively in diseased cells through nucleic acid or antibody delivery, (2) facilitating light-triggered release of therapeutic payloads, or (3) using cell-derived membranes as coatings to avoid detection by the immune system and deliver cargo to specific cells. Our research is at the forefront of nanomedicine, and is advancing the field by revealing important information regarding the design and implementation of nanoparticles for therapeutic applications. In the future, the technologies we develop may transform the way we manage diseases such as cancer, blood disorders, pregnancy-related conditions, and more.
For information about joining the lab, please email Dr. Day outlining your specific interests and attach a copy of your CV.
For a complete publication list, check Dr. Day’s Google Scholar.
- Riley RS, Day ES. Frizzled7 antibody-functionalized nanoshells enable multivalent binding for Wnt signaling inhibition in triple negative breast cancer cells. Small. 2017; doi: 10.1002/smll.201700544.
- Billingsley MM, Riley RS, Day ES. Antibody-nanoparticle conjugates to improve the sensitivity of ELISA-based detection methods. PLOS ONE. 2017; 12(5); e0177592.
- Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodality cancer treatment. WIRES Nanomedicine & Nanobiotechnology. 2017; e1449.
- Melamed JR, Riley RS, Valcourt DM, Day ES. Using gold nanoparticles to disrupt the tumor microenvironment: an emerging therapeutic strategy. ACS Nano. 2016; 10(12): 10631-10635.
- Fay BL, Melamed JR, Day ES. Nanoshell-mediated photothermal therapy can enhance chemotherapy in inflammatory breast cancer cells. International Journal of Nanomedicine. 2015; 10: 6931-6941.
- Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng C-Y, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes & Development. 2015; 29(7): 732-745.
- Melamed JR*, Edelstein RS*, Day ES. Elucidating the fundamental mechanisms of cell death triggered by photothermal therapy. ACS Nano. 2015; 9(1): 6-11. *Contributed equally.
- Jensen SA*, Day ES*, Ko CH*, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Science Translational Medicine. 2013; 5(209): 209ra152. *Contributed equally.
- Day ES, Zhang L, Thompson PA, Zawaski JA, Kaffes CC, Gaber MW, Blaney SM, West JL. Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine. 2012; 7(8): 1133-1148.
- Day ES, Thompson PA, Zhang L, Lewinski NA, Ahmed N, Drezek RA, Blaney SM, West JL. Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. Journal of Neuro-Oncology. 2011; 104(1): 55-63.